These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29938670)

  • 1. Effect of weight reduction on severity of lower urinary tract symptoms in obese men with benign prostatic hyperplasia.
    Ng CF; Yee CH; So WY; Yip SK; Wu E; Yau P
    Hong Kong Med J; 2017 Jun; 23 Suppl 2(3):35-37. PubMed ID: 29938670
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of weight reduction on the severity of lower urinary tract symptoms in obese male patients with benign prostatic hyperplasia: a randomized controlled trial.
    Yee CH; So WY; Yip SK; Wu E; Yau P; Ng CF
    Korean J Urol; 2015 Mar; 56(3):240-6; discussion 246-7. PubMed ID: 25763129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.
    Lepor H
    Urol Clin North Am; 2016 Aug; 43(3):311-23. PubMed ID: 27476124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
    Sarma AV; Wei JT
    N Engl J Med; 2012 Jul; 367(3):248-57. PubMed ID: 22808960
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study.
    Gravas S
    Eur Urol; 2015 Aug; 68(2):338-9. PubMed ID: 26149729
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
    Yuan JQ; Yang ZY; Mao C
    Eur Urol; 2012 Aug; 62(2):e35; author reply e36-8. PubMed ID: 22656724
    [No Abstract]   [Full Text] [Related]  

  • 7. Adherence to therapy for lower urinary tract symptoms: don't mistake association with causation!
    Penson DF
    Eur Urol; 2015 Sep; 68(3):426-7. PubMed ID: 25703576
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of benign prostatic hyperplasia.
    Nunes RV; Manzano J; Truzzi JC; Nardi A; Silvinato A; Bernardo WM;
    Rev Assoc Med Bras (1992); 2017 Feb; 63(2):95-99. PubMed ID: 28355368
    [No Abstract]   [Full Text] [Related]  

  • 9. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.
    Bae WJ; Bae JH; Kim SW; Chung BH; Kim JH; Kim CS; Lee HM; Lee KS; Yoo TK; Kim SI; Byun SS; Lee JY
    J Urol; 2013 Jul; 190(1):180-6. PubMed ID: 23357213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
    Kadekawa K; Sugaya K; Mukoyama H; Sakumoto M; Shimabukuro H; Shimabukuro S; Matayoshi Y; Onaga T; Ashitomi K; Nishijima S
    Low Urin Tract Symptoms; 2016 May; 8(2):100-5. PubMed ID: 27111621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
    Belayneh M; Korownyk C
    Can Fam Physician; 2016 Sep; 62(9):e523. PubMed ID: 27629686
    [No Abstract]   [Full Text] [Related]  

  • 15. [Medical therapy of male lower urinary tract symptoms].
    Gratzke C; Stief CG
    Urologe A; 2013 Feb; 52(2):184-5. PubMed ID: 23370400
    [No Abstract]   [Full Text] [Related]  

  • 16. The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia.
    Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Hirakawa A; Gotoh M
    Urology; 2016 Feb; 88():149-54. PubMed ID: 26592467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia.
    Sicras-Mainar A; Navarro-Artieda R; Mora AM; Hernández M
    BMC Urol; 2017 Sep; 17(1):83. PubMed ID: 28899370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
    Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
    J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.
    Jhang JF; Liao CH; Kuo HC
    Int J Clin Pract; 2014 Jun; 68(6):743-8. PubMed ID: 24471413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.